Donate to Remove ads

Got a credit card? use our Credit Card & Finance Calculators

Thanks to johnstevens77,Bhoddhisatva,scotia,Anonymous,Cornytiv34, for Donating to support the site

GlaxoSmithkline Announcement

For discussion of the practicalities of setting up and operating income-portfolios which follow the HYP Group Guidelines. READ Guidelines before posting
Forum rules
Tight HYP discussions only please - OT please discuss in strategies
idpickering
The full Lemon
Posts: 11276
Joined: November 4th, 2016, 5:04 pm
Has thanked: 2468 times
Been thanked: 5763 times

GlaxoSmithkline Announcement

#145531

Postby idpickering » June 14th, 2018, 7:05 am

Positive headline results for ViiV GEMINI studies

ViiV Healthcare reports landmark phase III studies for dolutegravir and lamivudine, demonstrating the ability to control HIV with a two-drug regimen in treatment naïve patients


https://www.investegate.co.uk/glaxosmit ... 00043780R/

monabri
Lemon Half
Posts: 8396
Joined: January 7th, 2017, 9:56 am
Has thanked: 1539 times
Been thanked: 3428 times

Re: GlaxoSmithkline Announcement

#145607

Postby monabri » June 14th, 2018, 1:42 pm

To counter ULVRs drop today, GSK is currently at 1576p ... increased from 1242p on Feb 6th 2018.

(even BT has a smile on it's face!)

idpickering
The full Lemon
Posts: 11276
Joined: November 4th, 2016, 5:04 pm
Has thanked: 2468 times
Been thanked: 5763 times

Re: GlaxoSmithkline Announcement

#145613

Postby idpickering » June 14th, 2018, 2:03 pm

monabri wrote:To counter ULVRs drop today, GSK is currently at 1576p ... increased from 1242p on Feb 6th 2018.

(even BT has a smile on it's face!)


Yes a nice 2.3% rise in SP from GSK currently, and BT.A up 2.9%. It's a funny old game this HYP lark. :)

Ian.

moorfield
Lemon Quarter
Posts: 3523
Joined: November 7th, 2016, 1:56 pm
Has thanked: 1546 times
Been thanked: 1402 times

Re: GlaxoSmithkline Announcement

#145641

Postby moorfield » June 14th, 2018, 5:03 pm

idpickering wrote:Positive headline results for ViiV GEMINI studies

ViiV Healthcare reports landmark phase III studies for dolutegravir and lamivudine, demonstrating the ability to control HIV with a two-drug regimen in treatment naïve patients


https://www.investegate.co.uk/glaxosmit ... 00043780R/



Directorspeak <-> English:

Well it looks like it might work.


Return to “HYP Practical (See Group Guidelines)”

Who is online

Users browsing this forum: No registered users and 15 guests